3 High-Yield S&P 500 Dividend Stocks Down More Than 25% to Buy Now and Hold for at Least a Decade
What are the projected earnings per share for Pfizer, and how do these compare to its current annual dividend commitment?
Pfizer's management predicts that the company's adjusted earnings per share will land in a range between $2.15 and $2.35. This is more than it needs to meet a dividend commitment currently set at an annualized $1.68 per share.
How have Pfizer's sales of Comirnaty and Paxlovid changed in the first quarter compared to the previous year?
In the first quarter, Pfizer's sales of Comirnaty and Paxlovid experienced a significant decline compared to the previous year. Combined sales of the two products fell more than 60% year over year to $2.4 billion. This decline is primarily attributed to a decrease in demand and contracted deliveries in both international and U.S. markets. Despite the sinking sales, Pfizer's dividend program remains strong, offering a substantial 6.1% yield. The company's adjusted earnings per share are expected to be in the range of $2.15 to $2.35, which is sufficient to meet its dividend commitment set at an annualized $1.68 per share.
What specific factors have contributed to the decline of Pfizer's stock by approximately 31% over the past 12 months?
The decline of Pfizer's stock by approximately 31% over the past 12 months can be attributed to several factors. One of the main factors is the decreasing demand for its COVID-19 products, Comirnaty and Paxlovid. Combined first-quarter sales of these products fell more than 60% year over year to $2.4 billion. Management predicts further declines for these drugs, which has negatively impacted the stock price. Additionally, the stock market has been focused on the sinking sales of these COVID-related products, further contributing to the decline in Pfizer's stock price.